US20080057063A1 - Antibodies Directed to AlphaVBeta6 and Uses Thereof - Google Patents
Antibodies Directed to AlphaVBeta6 and Uses Thereof Download PDFInfo
- Publication number
- US20080057063A1 US20080057063A1 US11/833,486 US83348607A US2008057063A1 US 20080057063 A1 US20080057063 A1 US 20080057063A1 US 83348607 A US83348607 A US 83348607A US 2008057063 A1 US2008057063 A1 US 2008057063A1
- Authority
- US
- United States
- Prior art keywords
- seq
- binding agent
- antibody
- αvβ6
- targeted binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/833,486 US20080057063A1 (en) | 2006-08-03 | 2007-08-03 | Antibodies Directed to AlphaVBeta6 and Uses Thereof |
US12/782,335 US8398975B2 (en) | 2006-08-03 | 2010-05-18 | Antibodies directed to αVβ6 and uses thereof |
US13/760,426 US8894998B2 (en) | 2006-08-03 | 2013-02-06 | Antibodies directed to αVβ6 and uses thereof |
US14/535,894 US20150166663A1 (en) | 2006-08-03 | 2014-11-07 | Antibodies Directed To Alpha V Beta 6 And Uses Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83555906P | 2006-08-03 | 2006-08-03 | |
US11/833,486 US20080057063A1 (en) | 2006-08-03 | 2007-08-03 | Antibodies Directed to AlphaVBeta6 and Uses Thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/782,335 Continuation US8398975B2 (en) | 2006-08-03 | 2010-05-18 | Antibodies directed to αVβ6 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080057063A1 true US20080057063A1 (en) | 2008-03-06 |
Family
ID=39146822
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/833,486 Abandoned US20080057063A1 (en) | 2006-08-03 | 2007-08-03 | Antibodies Directed to AlphaVBeta6 and Uses Thereof |
US12/782,335 Active 2028-08-20 US8398975B2 (en) | 2006-08-03 | 2010-05-18 | Antibodies directed to αVβ6 and uses thereof |
US13/760,426 Active US8894998B2 (en) | 2006-08-03 | 2013-02-06 | Antibodies directed to αVβ6 and uses thereof |
US14/535,894 Abandoned US20150166663A1 (en) | 2006-08-03 | 2014-11-07 | Antibodies Directed To Alpha V Beta 6 And Uses Thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/782,335 Active 2028-08-20 US8398975B2 (en) | 2006-08-03 | 2010-05-18 | Antibodies directed to αVβ6 and uses thereof |
US13/760,426 Active US8894998B2 (en) | 2006-08-03 | 2013-02-06 | Antibodies directed to αVβ6 and uses thereof |
US14/535,894 Abandoned US20150166663A1 (en) | 2006-08-03 | 2014-11-07 | Antibodies Directed To Alpha V Beta 6 And Uses Thereof |
Country Status (18)
Country | Link |
---|---|
US (4) | US20080057063A1 (es) |
EP (1) | EP2064244B1 (es) |
JP (2) | JP5362563B2 (es) |
KR (1) | KR20090039739A (es) |
CN (2) | CN103524619B (es) |
AR (1) | AR062213A1 (es) |
AU (1) | AU2007348941B2 (es) |
BR (1) | BRPI0715141A2 (es) |
CA (1) | CA2658612C (es) |
ES (1) | ES2746925T3 (es) |
IL (1) | IL196848A0 (es) |
MX (1) | MX2009001293A (es) |
NO (1) | NO20090877L (es) |
RU (1) | RU2009107277A (es) |
TW (1) | TW200815474A (es) |
UY (1) | UY30524A1 (es) |
WO (1) | WO2008112004A2 (es) |
ZA (1) | ZA200900395B (es) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100172895A1 (en) * | 2008-12-23 | 2010-07-08 | Boone Thomas C | Human CGRP Receptor Binding Proteins |
US20100330103A1 (en) * | 2006-08-03 | 2010-12-30 | Astrazeneca Ab | Antibodies Directed to Alpha V Beta 6 And Uses Thereof |
CN102858975A (zh) * | 2010-02-18 | 2013-01-02 | 明治制果药业株式会社 | 铜绿假单胞菌a血清型脂多糖的抗体 |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US20140199295A1 (en) * | 2011-06-23 | 2014-07-17 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016057306A1 (en) * | 2014-10-06 | 2016-04-14 | University Of Houston | Rho associated kinase (rock) inhibitors and their use in treating disease |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
WO2016090329A3 (en) * | 2014-12-05 | 2016-07-28 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
US9573992B2 (en) | 2011-06-23 | 2017-02-21 | Ablynx N.V. | Serum albumin binding proteins |
EP3042956A4 (en) * | 2013-09-05 | 2017-03-15 | University of Miyazaki | Antibody which specifically reacts with human integrin a6b4 |
US9683045B2 (en) | 2010-09-30 | 2017-06-20 | Ablynx N.V. | Biological materials related to c-Met |
WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
AU2016244220B2 (en) * | 2008-12-23 | 2018-05-17 | Amgen Inc. | Human CGRP receptor binding proteins |
US10259877B2 (en) | 2015-04-24 | 2019-04-16 | Amgen Inc. | Methods for treating or preventing migraine headache |
CN109843911A (zh) * | 2016-08-18 | 2019-06-04 | 国家生物技术研究所公司 | 用于治疗骨相关疾病的组合物和方法 |
WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
US20200095317A1 (en) * | 2018-05-09 | 2020-03-26 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
US10633426B2 (en) | 2014-12-05 | 2020-04-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof |
US10934362B2 (en) | 2014-09-15 | 2021-03-02 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
CN112533948A (zh) * | 2018-05-31 | 2021-03-19 | 台湾醣联生技医药股份有限公司 | 与双触角Lewis B以及Lewis Y抗原结合的治疗性抗体 |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
US11407838B2 (en) | 2018-04-02 | 2022-08-09 | Amgen Inc. | Erenumab compositions and uses thereof |
US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US11975076B2 (en) | 2015-11-25 | 2024-05-07 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010072741A1 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR |
EP2385955B1 (en) * | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
SG11201404354UA (en) | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
US8834881B2 (en) | 2012-03-08 | 2014-09-16 | Crucell Holland B.V. | Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof |
EP2784511A1 (en) | 2013-03-27 | 2014-10-01 | Universität Zürich | Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma |
CN106232625B (zh) * | 2013-10-01 | 2020-04-24 | 免疫医疗有限公司 | 治疗和诊断过表达α-V-β-6的癌症的方法 |
WO2015085179A1 (en) * | 2013-12-06 | 2015-06-11 | The Regents Of The University Of California | Alpha-v beta-6 integrin-binding antibody fragments |
US20170233452A1 (en) * | 2014-04-23 | 2017-08-17 | Immusoft Corporation | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer |
TN2018000417A1 (en) * | 2016-06-14 | 2020-06-15 | Adimab Llc | Anti-coagulation factor xi antibodies. |
CN107991481A (zh) * | 2016-10-27 | 2018-05-04 | 武汉科前生物股份有限公司 | 一种检测猪伪狂犬病毒和口蹄疫病毒的二联阻断elisa抗体检测试剂盒及其应用 |
KR102634762B1 (ko) * | 2016-11-01 | 2024-02-06 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-v 베타-6 인테그린 리간드 및 그의 용도 |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112215A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
MX2022006132A (es) | 2019-12-05 | 2022-06-17 | Seagen Inc | Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
CN114195893A (zh) * | 2020-09-17 | 2022-03-18 | 百奥泰生物制药股份有限公司 | 抗整联蛋白抗体或抗原结合片段及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US20080152587A1 (en) * | 2006-04-10 | 2008-06-26 | Amgen Fremont Inc. | TARGETED BINDING AGENTS DIRECTED TO uPAR AND USES THEREOF |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) * | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE69133557D1 (de) * | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) * | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
NZ253943A (en) | 1992-06-18 | 1997-01-29 | Genpharm Int | Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US5981175A (en) * | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5625825A (en) * | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
DK0843961T3 (da) | 1995-08-29 | 2007-05-21 | Kirin Brewery | Kimærisk mus og fremgangsmåde til at producere samme |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
AU739283B2 (en) * | 1997-08-08 | 2001-10-11 | Regents Of The University Of California, The | Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6 |
HUP0101151A3 (en) | 1998-01-23 | 2004-06-28 | Merck Patent Gmbh | Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin |
CA2355874A1 (en) | 1998-12-19 | 2000-06-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | .alpha.v.beta.6 integrin inhibitors |
US6521593B1 (en) | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
DE19929410A1 (de) | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
DE19933173A1 (de) | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
IL164021A0 (en) * | 2002-03-13 | 2005-12-18 | Univ California | Antibodies and anti-pharmaceutical compositions containing the same |
EP1492870A4 (en) * | 2002-04-12 | 2005-08-03 | Raven Biotechnologies Inc | ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF |
EA013323B1 (ru) * | 2004-12-09 | 2010-04-30 | Сентокор, Инк. | Иммуноконъюгаты против интегрина, способы и варианты применения |
CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
MX2009001293A (es) * | 2006-08-03 | 2009-02-11 | Astrazeneca Ab | Anticuerpos dirigidos a (v(6 y usos de los mismos. |
JP2010506944A (ja) | 2006-10-19 | 2010-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαVβ6のアンタゴニストを用いる慢性喘息の処置および予防 |
US20090163698A1 (en) * | 2007-05-11 | 2009-06-25 | John Joseph Grigsby | Method for Preparing Antibody Conjugates |
US20090175784A1 (en) * | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
US20090196913A1 (en) * | 2007-05-11 | 2009-08-06 | Ken Shi Kun Huang | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
GB0718843D0 (en) | 2007-09-26 | 2007-11-07 | Cancer Rec Tech Ltd | Materials and methods relating to modifying the binding of antibodies |
-
2007
- 2007-08-02 MX MX2009001293A patent/MX2009001293A/es not_active Application Discontinuation
- 2007-08-02 JP JP2009523064A patent/JP5362563B2/ja active Active
- 2007-08-02 WO PCT/US2007/075120 patent/WO2008112004A2/en active Application Filing
- 2007-08-02 TW TW096128378A patent/TW200815474A/zh unknown
- 2007-08-02 ES ES07873972T patent/ES2746925T3/es active Active
- 2007-08-02 AU AU2007348941A patent/AU2007348941B2/en active Active
- 2007-08-02 RU RU2009107277/10A patent/RU2009107277A/ru not_active Application Discontinuation
- 2007-08-02 KR KR1020097002131A patent/KR20090039739A/ko not_active Application Discontinuation
- 2007-08-02 BR BRPI0715141-1A patent/BRPI0715141A2/pt not_active Application Discontinuation
- 2007-08-02 CN CN201310233421.4A patent/CN103524619B/zh not_active Expired - Fee Related
- 2007-08-02 EP EP07873972.9A patent/EP2064244B1/en active Active
- 2007-08-02 CA CA2658612A patent/CA2658612C/en active Active
- 2007-08-02 CN CN2007800372515A patent/CN101553505B/zh active Active
- 2007-08-03 UY UY30524A patent/UY30524A1/es not_active Application Discontinuation
- 2007-08-03 US US11/833,486 patent/US20080057063A1/en not_active Abandoned
- 2007-08-03 AR ARP070103452A patent/AR062213A1/es unknown
-
2009
- 2009-01-16 ZA ZA200900395A patent/ZA200900395B/xx unknown
- 2009-02-02 IL IL196848A patent/IL196848A0/en unknown
- 2009-02-25 NO NO20090877A patent/NO20090877L/no not_active Application Discontinuation
-
2010
- 2010-05-18 US US12/782,335 patent/US8398975B2/en active Active
-
2013
- 2013-02-06 US US13/760,426 patent/US8894998B2/en active Active
- 2013-07-17 JP JP2013148794A patent/JP2013256504A/ja active Pending
-
2014
- 2014-11-07 US US14/535,894 patent/US20150166663A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US20080152587A1 (en) * | 2006-04-10 | 2008-06-26 | Amgen Fremont Inc. | TARGETED BINDING AGENTS DIRECTED TO uPAR AND USES THEREOF |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8894998B2 (en) | 2006-08-03 | 2014-11-25 | Medimmune Limited | Antibodies directed to αVβ6 and uses thereof |
US8398975B2 (en) | 2006-08-03 | 2013-03-19 | Medimmune Limited | Antibodies directed to αVβ6 and uses thereof |
US20100330103A1 (en) * | 2006-08-03 | 2010-12-30 | Astrazeneca Ab | Antibodies Directed to Alpha V Beta 6 And Uses Thereof |
AU2018203471B2 (en) * | 2008-12-23 | 2020-03-05 | Amgen Inc. | Human CGRP receptor binding proteins |
US20100172895A1 (en) * | 2008-12-23 | 2010-07-08 | Boone Thomas C | Human CGRP Receptor Binding Proteins |
AU2016244220B2 (en) * | 2008-12-23 | 2018-05-17 | Amgen Inc. | Human CGRP receptor binding proteins |
AU2009330175B2 (en) * | 2008-12-23 | 2014-01-16 | Amgen Inc. | Human CGRP receptor binding proteins |
US9862771B2 (en) | 2008-12-23 | 2018-01-09 | Amgen Inc. | Human CGRP receptor binding proteins |
US9102731B2 (en) | 2008-12-23 | 2015-08-11 | Amgen Inc. | Human CGRP receptor binding proteins |
AU2013205271C1 (en) * | 2008-12-23 | 2018-10-04 | Amgen Inc. | Human CGRP receptor binding proteins |
AU2009330175C1 (en) * | 2008-12-23 | 2018-10-04 | Amgen Inc. | Human CGRP receptor binding proteins |
CN102858975A (zh) * | 2010-02-18 | 2013-01-02 | 明治制果药业株式会社 | 铜绿假单胞菌a血清型脂多糖的抗体 |
US20130045207A1 (en) * | 2010-02-18 | 2013-02-21 | Symphogen A/S | Antibody against serotype g lipopolysaccharide of pseudomonas aeruginosa |
US20130004499A1 (en) * | 2010-02-18 | 2013-01-03 | Symphogen A/S | Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa |
US9683045B2 (en) | 2010-09-30 | 2017-06-20 | Ablynx N.V. | Biological materials related to c-Met |
US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US20140199295A1 (en) * | 2011-06-23 | 2014-07-17 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US11192937B2 (en) | 2011-06-23 | 2021-12-07 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US10858418B2 (en) | 2011-06-23 | 2020-12-08 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US9573992B2 (en) | 2011-06-23 | 2017-02-21 | Ablynx N.V. | Serum albumin binding proteins |
US11192938B2 (en) | 2011-06-23 | 2021-12-07 | Ablynx N.V. | Serum albumin binding proteins containing immunoglobulin single variable domains |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
EP2839860A1 (en) | 2012-10-12 | 2015-02-25 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
EP3042956A4 (en) * | 2013-09-05 | 2017-03-15 | University of Miyazaki | Antibody which specifically reacts with human integrin a6b4 |
US10030071B2 (en) | 2013-09-05 | 2018-07-24 | University Of Miyazaki | Antibody which specifically reacts with human integrin A6B4 |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11919964B2 (en) | 2014-09-15 | 2024-03-05 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
US10934362B2 (en) | 2014-09-15 | 2021-03-02 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
WO2016057306A1 (en) * | 2014-10-06 | 2016-04-14 | University Of Houston | Rho associated kinase (rock) inhibitors and their use in treating disease |
US10335449B2 (en) | 2014-10-06 | 2019-07-02 | University Of Houston System | Rho associated kinase (ROCK) inhibitors and their use in treating disease |
US11566071B2 (en) | 2014-12-05 | 2023-01-31 | Memorial Sloan Kettering Cancer Center | Nucleic acid molecules encoding anti-GPRC5D antibodies |
WO2016090329A3 (en) * | 2014-12-05 | 2016-07-28 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
US11820806B2 (en) | 2014-12-05 | 2023-11-21 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof |
US10906956B2 (en) | 2014-12-05 | 2021-02-02 | Memorial Sloan Kettering Cancer Center | Methods of treatments using chimeric antigen receptors targeting G-protein coupled receptor |
US10590196B2 (en) | 2014-12-05 | 2020-03-17 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting G-protein coupled receptor and methods of use |
US10633426B2 (en) | 2014-12-05 | 2020-04-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof |
US11866478B2 (en) | 2014-12-05 | 2024-01-09 | Memorial Sloan-Kettering Cancer Center | Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor |
US11466090B2 (en) | 2015-04-24 | 2022-10-11 | Amgen Inc. | Methods for treating or preventing migraine headache |
US10259877B2 (en) | 2015-04-24 | 2019-04-16 | Amgen Inc. | Methods for treating or preventing migraine headache |
US11975076B2 (en) | 2015-11-25 | 2024-05-07 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
CN109843911A (zh) * | 2016-08-18 | 2019-06-04 | 国家生物技术研究所公司 | 用于治疗骨相关疾病的组合物和方法 |
WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
US11407838B2 (en) | 2018-04-02 | 2022-08-09 | Amgen Inc. | Erenumab compositions and uses thereof |
US20200095317A1 (en) * | 2018-05-09 | 2020-03-26 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
US11827703B2 (en) * | 2018-05-09 | 2023-11-28 | Legochem Biosciences, Inc. | Compositions and methods related to anti-CD19 antibody drug conjugates |
WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
CN112533948A (zh) * | 2018-05-31 | 2021-03-19 | 台湾醣联生技医药股份有限公司 | 与双触角Lewis B以及Lewis Y抗原结合的治疗性抗体 |
WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Also Published As
Publication number | Publication date |
---|---|
KR20090039739A (ko) | 2009-04-22 |
CA2658612A1 (en) | 2008-09-18 |
TW200815474A (en) | 2008-04-01 |
MX2009001293A (es) | 2009-02-11 |
US8398975B2 (en) | 2013-03-19 |
UY30524A1 (es) | 2008-02-29 |
IL196848A0 (en) | 2011-08-01 |
CN101553505A (zh) | 2009-10-07 |
US8894998B2 (en) | 2014-11-25 |
WO2008112004A3 (en) | 2009-04-02 |
ES2746925T3 (es) | 2020-03-09 |
AU2007348941B2 (en) | 2011-08-04 |
CN103524619A (zh) | 2014-01-22 |
JP5362563B2 (ja) | 2013-12-11 |
AR062213A1 (es) | 2008-10-22 |
NO20090877L (no) | 2009-03-03 |
US20150166663A1 (en) | 2015-06-18 |
JP2009545327A (ja) | 2009-12-24 |
US20130202621A1 (en) | 2013-08-08 |
BRPI0715141A2 (pt) | 2013-06-04 |
ZA200900395B (en) | 2010-01-27 |
RU2009107277A (ru) | 2010-09-10 |
CN103524619B (zh) | 2016-10-05 |
CA2658612C (en) | 2015-11-17 |
EP2064244B1 (en) | 2019-06-05 |
AU2007348941A1 (en) | 2008-09-18 |
CN101553505B (zh) | 2013-07-17 |
US20100330103A1 (en) | 2010-12-30 |
EP2064244A2 (en) | 2009-06-03 |
JP2013256504A (ja) | 2013-12-26 |
WO2008112004A2 (en) | 2008-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2658612C (en) | Antibodies directed to .alpha.v.beta.6 and uses thereof | |
US20120107324A1 (en) | TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF | |
US20190389967A1 (en) | Method of treating and diagnosing alpha-v-beta-6 overexpressing cancer | |
US8119130B2 (en) | Targeted binding agents directed to KDR and uses thereof—035 | |
US8697664B2 (en) | Targeted binding agents directed to PDGRF-alpha and uses thereof | |
US20120114667A1 (en) | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF | |
WO2010072741A1 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALFRED, AVRIL;BARRY, SIMON THOMAS;BEDIAN, VAHE;AND OTHERS;REEL/FRAME:021755/0151;SIGNING DATES FROM 20080212 TO 20080818 Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMGEN FREMONT INC;REEL/FRAME:021755/0950 Effective date: 20070425 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: MEDIMMUNE LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA AB;REEL/FRAME:025790/0810 Effective date: 20110208 |